

Available online at [www.ijppronline.in](http://www.ijppronline.in)

# International Journal of Pharma Professional Research



ISSN NO:0976-6723

## Research Article

### FORMULATION AND EVALUATION OF FLOATING MICROSPHERE OF RANITIDINE HYDROCHLORIDE

Vinod Kumar<sup>\*1</sup>, Pawan Jalwal<sup>1</sup>, Nirja, Jyoti, Tanuj Hooda<sup>2</sup>

1. Shri Baba Mastnath Institute of Pharmaceutical Sciences & Research, Asthal Bohar, Rohtak-124001

2. Vaish Institute of Pharmaceutical Education and Research, Rohtak, Haryana


#### Abstract

Ranitidine HCl is H<sub>2</sub> receptor antagonist inhibits acid production by reversibly competing with histamine for binding to H<sub>2</sub> receptors on the basolateral membrane of parietal cells. It competitively inhibits histamine action at all H<sub>2</sub> receptors but their main clinical use is as inhibition of gastric acid secretion. It inhibited histamine stimulation and gastrin stimulated acid secretion. The microspheres of each batch were subjected to various physicochemical studies i.e. particle size, bulk density, % yield, % buoyancy, drug entrapment efficiency etc. The compatibility of the drug with selected polymers was determined by FTIR spectrophotometric studies using FTIR Affinity -1. The characteristic peaks of pure drug, ethyl cellulose and chitosan were compared with that obtained with the formulation of all the nine batches. Thin layer chromatography was performed and studied comparative to the pure drug and its micro spherical formulations.

**Keywords:** Microsphere, Ranitidine, histamine receptor, FTIR etc.

#### Introduction

Ranitidine is a H<sub>2</sub> antihistamine drug. It is a drug used to block the action of histamine on parietal cells in the stomach decreasing acid production by these cells. It has a furan ring. It has melting point 69-70 °C. The wavelength of ranitidine is at 229 nm and 315 nm (water used as medium). The chemical name of Ranitidine HCl is N [2-[[[5-[(dimethylamino) methyl]-2-furanyl] methyl] thio]ethyl]-N<sup>1</sup>-methyl-2-nitro-1,1-ethenediamine, HCl.



**Figure 1: Structure of Ranitidine Hydrochloride**

It was a white or pale yellow crystalline powder drug having melting point 136-142 °C. It is freely soluble in water, methanol and ethanol (95%), sparingly soluble in ethanol, very slightly soluble in chloroform and in dichloro methane.

The molecular formula of Ranitidine HCl is and

C<sub>13</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>S•HCl and the molecular weight is 350.87. It is preserve in well closed container, Protected from light. Ranitidine HCl is H<sub>2</sub> receptor antagonist inhibits acid production by reversibly competing with histamine for binding to H<sub>2</sub> receptors on the basolateral membrane of parietal cells. It competitively inhibits histamine action at all H<sub>2</sub> receptors but their main clinical use is as inhibition of gastric acid secretion. It inhibited histamine stimulation and gastrin stimulated acid secretion. It decreases both basal and food stimulated acid secretion by 90% or more, but promote healing of duodenal ulcer. Specific ranitidine uses include treatment or prevention of the following conditions:

- Duodenal ulcers, Gastric ulcers (stomach ulcers), Gastroesophageal reflux disease (GERD) and Erosive esophagitis
- Pathological hypersecretory conditions (in which too much stomach acid is produced), such as Zollinger-Ellison syndrome.
- Over-the-counter ranitidine is approved for the following conditions in people 12 years

older: Heartburn, Acid indigestion and Sour stomach.

**Adverse Effects**

- Constipation, Diarrohoea, Headache, Stomach upset, change in the amount of urine produced; confusion, dark urine and depression
- fast, slow, or irregular heartbeat, fever, chills, or sore throat; Yellowing of the eyes or skin and Hallucination
- rash, urticaria, bronchospasm, fever, eosinophilia, angioneurotic edema, acute eosinophilic pneumonia and anaphylaxis

- to decrease mucosal perfusion in patients with acute renal or cardiac failure and increases their risk of death
  - class decrease gastric intrinsic factor secretion which can significantly reduce absorption of protein-bound vitamin B<sub>12</sub> in humans
  - may increase the risk of pneumonia in hospitalized patients
  - increase the risk of developing food allergies
- Thrombocytopenia

**Table 1: Pharmacokinetics of Ranitidine**

|   |  |
|---|--|
| Bioavailability                               | 45-50%   |
| Plasma Half Life                              | 2 hrs.   |
| Plasma Protein Binding                        | 15- 20%  |
| Peak Plasma Concentration (C <sub>max</sub> ) | 1- 3 hours   |
| Excretion                                     | Renal Excretion (65-70%)<br>Metabolic Excretion (30-35%)   |
| Renal Clearance                               | 600 ml/min   |
| Drug Interaction                              | It does not inhibit hepatic microsomal enzyme CYTP450 system and hence does not interact with drugs which are substrate for CYTP450 systems like Warfarin, Pheytoin, Quinidine, Caffiene etc. It does not block androgen receptors and do not cause Gynaecomastia and impotence like cimetidine. |

**Materials and Methods**

Ranitidine was received as a gift sample from Panacea biotech, Mohali. Ethyl cellulose was received as a gift samples from Fine Chem. Labs. Mumbai. Chitosan, PVA and SLS were purchased from Signet Chemical Corporation. Tween 80 and HCl were purchased from Rankem. 99% ethanol was purchased from Jiangsu Huaxi International.

**Experimental work**

**Formulation design of Ranitidine HCl**

Microspheres containing Ranitidine HCl as a core material were prepared by emulsion solvent diffusion method. Drug and polymer were dispersed in the solvent (dichloromethane and ethanol in ratio 1:1 v/v). The slurry was slowly introduced into 200 ml of water containing (0.75% w/v) polyvinyl alcohol maintained at a constant temperature of 40 °C with continuous stirring at 300 rpm using a propeller type mechanical stirrer. The solution was stirred for 2 hrs. The finely developed floating microspheres were separated by filtration washed with water &

dried at room temperature in a dessicator for 24 hrs. The formulation was divided into nine batches prepared with different ratio of suitably chosen polymers as depicted in the table below .

**Evaluation of floating microspheres**

**Micromeritic parameters**

Micromeritic parameters like bulk density, tapped density, carr’s index, angle of repose and hausner’s ratio for formulations (F<sub>1</sub>-F<sub>9</sub>) were determined and found in the range of (0.24-0.68) (0.32-0.86) (14.46-23) & (12.14-18.16) respectively.

**Particle Size Determination**

The particle size determination was performed for all nine batches. Results were as shown in table 4. The mean particle size was found to be in the range of 128.80 - 196.21µm.

**Surface morphology**

The surface morphology of microspheres was examined by scanning electron microscopy.

**Table 2: Formulation design of microspheres**


| Ingredients     | Formulation Codes |       |       |       |       |       |        |         |         |
|-----------------|-------------------|-------|-------|-------|-------|-------|--------|---------|---------|
|                 | F1                | F2    | F3    | F4    | F5    | F6    | F7     | F8      | F9      |
| Rantidine HCl   | 100               | 100   | 100   | 100   | 100   | 100   | 100    | 100     | 100     |
| Ethyl cellulose | 100               | 150   | 200   | -     | -     | -     | -      | -       | -       |
| Chitosan        | -                 | -     | -     | 100   | 150   | 200   | -      | -       | -       |
| Chitosan+ EC    | -                 | -     | -     | -     | -     | -     | 50:150 | 100:100 | 150: 50 |
| Dichloromethane | 10                | 10    | 10    | 10    | 10    | 10    | 10     | 10      | 10      |
| Ethanol         | 10                | 10    | 10    | 10    | 10    | 10    | 10     | 10      | 10      |
| SLS (mg)        | 20                | 20    | 20    | 20    | 20    | 20    | 20     | 20      | 20      |
| Tween 80        | 0.01%             | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01%  | 0.01%   | 0.01%   |
| PVA (w/v %)     | 0.75              | 0.75  | 0.75  | 0.75  | 0.75  | 0.75  | 0.75   | 0.75    | 0.75    |

**Table 3: Results of Micromeritic parameters**

| S. No. | Formulation Code | Bulk Density (gm/ml) | Tapped Density (gm/ml) | Carr's Index (%) | Angle of repose (θ) |
|--------|------------------|----------------------|------------------------|------------------|---------------------|
| 1      | F1               | 0.3435               | 0.4640                 | 22.56            | 12.14               |
| 2      | F2               | 0.2408               | 0.3285                 | 23.00            | 18.16               |
| 3      | F3               | 0.4502               | 0.5688                 | 18.50            | 15.67               |
| 4      | F4               | 0.2408               | 0.3476                 | 16.28            | 15.34               |
| 5      | F5               | 0.3683               | 0.4580                 | 18.67            | 14.76               |
| 6      | F6               | 0.3566               | 0.4143                 | 15.28            | 15.98               |
| 7      | F7               | 0.6823               | 0.8653                 | 21.00            | 12.32               |
| 8      | F8               | 0.5500               | 0.67400                | 17.67            | 14.34               |
| 9      | F9               | 0.4429               | 0.4835                 | 14.46            | 16.14               |

**Tablet 4: Particle size for batch F1 - F9**

| Serial no. | Formulation code | Size (µm) |
|------------|------------------|-----------|
| 1          | F1               | 134.10    |
| 2          | F2               | 133.44    |
| 3          | F3               | 157.23    |
| 4          | F4               | 139.10    |
| 5          | F5               | 144.92    |
| 6          | F6               | 128.80    |
| 7          | F7               | 189.65    |
| 8          | F8               | 196.21    |
| 9          | F9               | 192.53    |



**Figure 2: SEM photomicrographs of micro spherical particles**

It revealed rough texture of microspheres with minute dents on the surface.

**Percentage Buoyancy**

The buoyancy test was carried out to investigate the floatability of the prepared microspheres. The particles were spread over the surface of a simulated gastric fluid and the fraction of microspheres settled down as a function of time was quantities. The fraction of microspheres reduced up to 12 hrs suggested that the absorption of the drug in vivo pertaining to sustained release would be linear with time.

Buoyancy of Formulations F3, F8, F9 were found to be 65.39%, 65.45% and 65.41% respectively thus indicating that microspheres were still floatable even after 12 hrs.

**Drug Entrapment Efficiency**

The microspheres of batch F3, F6 and F7 formulations showed entrapment of 69.77%, 77.57%, 80.42% respectively while formulations F1 and F4 particles were least entrapped. It attributed to the permeation characteristics of each polymer.

**Percentage Yield**

The maximum % yield was found to be 79.60% with batch F7 and minimum of 66.92% with F6 batch.


**In vitro dissolution study  
Correlation coefficient (R<sup>2</sup>) and diffusion exponent (n) after fitting of dissolution data (simulated gastric fluid) into various releases kinetic models:**

All the release data were fitted into various kinetic models like, zero order, First order, Higuchi and Korsmeyer-peppas in order to find out the mechanism of drug release from polymeric microspheres. The correlation & diffusion coefficients were calculated as summarized in table.

Analysis of the release data as per zero order kinetic model best suited to describe the release rate of drug from the microspheres. When the release data was analyzed as per peppas equation, the release exponent 'n' was in the range of (0.531-0.742) with all the microspheres indicating non-fickian diffusion. Higuchi's plots resulted in linearity (r<sup>2</sup>> 0.932) indicating non-fickian diffusion mechanism.

**Table 5: Percentage buoyancy for batch F1 - F9**


| Sr. No. | Formulation Code | % Buoyancy |
|---------|------------------|------------|
| 1       | F1               | 56.91      |
| 2       | F2               | 63.60      |
| 3       | F3               | 65.39      |
| 4       | F4               | 52.72      |
| 5       | F5               | 53.59      |
| 6       | F6               | 55.57      |
| 7       | F7               | 60.52      |
| 8       | F8               | 65.45      |
| 9       | F9               | 65.41      |



**Figure 3 % Buoyancy of Formulation F1-F9**

**Table 6: Percentage Entrapment for batch F1 - F9**


| Formulation Code | % Entrapment |
|------------------|--------------|
| F1               | 51.91        |
| F2               | 64.60        |
| F3               | 69.77        |
| F4               | 56.24        |
| F5               | 69.51        |
| F6               | 77.57        |
| F7               | 80.42        |
| F8               | 60.87        |
| F9               | 62.99        |



**Figure 4: % Entrapment of Formulation F1-F9**

**Table 7: Percentage Yield for batch F1 - F9**

| Formulation | Percentage Yield (%) |
|-------------|----------------------|
| F1          | 78.20                |
| F2          | 76.80                |
| F3          | 72.60                |
| F4          | 75.60                |
| F5          | 70.10                |
| F6          | 66.92                |
| F7          | 79.60                |
| F8          | 77.14                |
| F9          | 72.90                |



**Figure 5: % Yield of Formulation F1-F9**

**Table 8: Kinetic values of batch F1- F9 in simulated gastric fluid**

| Formulation code | Zero order equation |                   | First order equation |                   | Higuchi's equation |                   | Korsmeyer's equation |                   |
|------------------|---------------------|-------------------|----------------------|-------------------|--------------------|-------------------|----------------------|-------------------|
|                  | (n)                 | (R <sup>2</sup> ) | (n)                  | (R <sup>2</sup> ) | (n)                | (R <sup>2</sup> ) | (n)                  | (R <sup>2</sup> ) |
| F1               | 0.056               | 0.849             | 0.00                 | 0.703             | 1.924              | 0.919             | 0.289                | 0.915             |
| F2               | 0.067               | 0.877             | 0.00                 | 0.754             | 2.089              | 0.948             | 0.312                | 0.963             |
| F3               | 0.053               | 0.843             | 0.00                 | 0.706             | 1.869              | 0.916             | 0.335                | 0.915             |
| F4               | 0.091               | 0.932             | 0.00                 | 0.805             | 3.178              | 0.984             | 0.521                | 0.985             |
| F5               | 0.087               | 0.876             | 0.00                 | 0.734             | 3.07               | 0.952             | 0.491                | 0.968             |
| F6               | 0.084               | 0.936             | 0.00                 | 0.863             | 2.895              | 0.979             | 0.469                | 0.986             |
| F7               | 1.065               | 0.989             | 0.001                | 0.630             | 2.236              | 0.970             | 0.679                | 0.889             |
| F8               | 0.057               | 0.913             | 0.00                 | 0.783             | 1.889              | 0.982             | 0.425                | 0.818             |
| F9               | 0.059               | 0.885             | 0.001                | 0.686             | 2.069              | 0.964             | 0.742                | 0.948             |

The comparative studies conducted with F2 F6 & F7 (best representatives from each class of formulation design) revealed F<sub>7</sub> as the overall optimized batch which was further subjected to accelerated stability studies and content uniformity test.

#### Summary

Three batches (F1, F2 & F3) of microspheres using the drug: ethyl cellulose (polymer) ratio of 1:1, 1:2 & 1:3 respectively, three batches (F4, F5 & F6) comprising drug: chitosan (polymer) ratio of 1:1, 1:2 & 1:3 respectively and three batches (F7, F8, & F9) comprising drug: chitosan: ethyl cellulose in the ratio of 1:0.5:1.5, 1:1:1 & 1:0.5:2.5 respectively were produced by Emulsion solvent diffusion method.

The microspheres of each batch were subjected to various physicochemical studies i.e. particle size, bulk density, % yield, % buoyancy, drug entrapment efficiency etc. The compatibility of the drug with selected polymers was determined by FTIR spectrophotometric studies using FTIR Affinity -1. The characteristic peaks of pure drug, ethyl cellulose and chitosan were compared with that obtained with the formulation of all the nine batches. Thin layer chromatography was performed and studied comparative to the pure drug and its micro spherical formulations.

The particles size was determined by scanning electron microscopy and bulk density was reckoned by hand trapping method. Other parameters such as % yield, buoyancy %, drug entrapment efficiency etc. were determined by traditional methods available so far. The in-vitro dissolution studies were carried out on dissolution apparatus (Electrolab, TDT 06L, 6 basket) in pH 1.2 HCl buffer and simulated gastric fluid.

#### Conclusion

The microspheres of Ranitidine HCl were prepared with two polymers i.e. ethyl cellulose and chitosan. The particle size determination by SEM techniques revealed that the mean particle diameter was in the range of 128.80 - 196.21µm. The mean particle size were in the order of F<sub>2</sub><F<sub>1</sub> < F<sub>6</sub> < F<sub>4</sub> < F<sub>5</sub> < F<sub>3</sub> < F<sub>7</sub> < F<sub>9</sub>< F<sub>8</sub>. The other physicochemical parameters determined with the microspheres were bulk density (0.24-0.68g/ml), particle size distribution (128.80-196.21µm), % yield (66.92%-79.60%), buoyancy % in pH 1.2 HCl buffer (52.72%- 65.45%), tapped density (0.32-0.86g/ml) and drug entrapment efficiency (51.91%-80.42%). The in vitro drug release in pH 1.2 HCl buffer ranged from 84.54%-55.10% while in simulated gastric fluid it ranged from 84.82%-56.76%. The overall determinations suggested F<sub>7</sub> batch as the best formulation. Conclusively % yield was maximum with F<sub>7</sub> and minimum with F<sub>6</sub> batch. The drug entrapment efficiency was found to be of the order F<sub>1</sub> < F<sub>7</sub> < F<sub>4</sub> < F<sub>8</sub> < F<sub>2</sub> < F<sub>9</sub> < F<sub>5</sub> < F<sub>3</sub> < F<sub>6</sub>.The overall determinations suggested F<sub>7</sub> as the best formulation. The in-vitro release of formulation F<sub>7</sub> in pH1.2 HCl buffer and in simulated gastric fluid (SGF) were 60.52% and 59.62% respectively which showed sustained release over a period of 12 hrs. All above data satisfactorily complied with the characteristics requirements of the formulation as gastroretentive microspheres.

The present worker tended to provide impetus for future researchers to design such novel drug delivery systems which can supersede conventional dosage forms with significant pharmacokinetic and pharmacodynamic properties.

**References:-**

- 1.S. Ramachandran, G. Thirumurugan and M.D. Dhanaraju, 2011. Development and Evaluation of Biodegradable Chitosan Microspheres Loaded with Ranitidine and Cross Linked with Gluteraldehyde. American Journal of Drug Discovery and Development, 1: 105-120.
- 2.Somasundaram Ramachandran\*, Satyamoorthy Nandhakumar1, Magharla Dasaratha DhanaRaju1 (2011) Development and in vitro Evaluation of Biodegradable Chitosan Microspheres Loaded with Ranitidine and Cross Linked with Gluteraldehyde International Journal of PharmTech Research Vol.3, No.1, pp 488-496.
- 3.Sarlesh rajput1, Preeti agrawal1, Ashish Pathak1, Nikhil Shrivatsava2, Satyendra Singh Baghel2, Rajendra singh baghel2 (2011) A Review on Microspheres: Methods of Prepration And Evalution World Journal of Pharmacy and Pharmaceutical Sciences Vol.1 pp 428-433.
- 4.Akash Yadav\* and Dinesh Kumar Jain Research Article on Formulation and evaluation of mucoadhesive microspheres of propranolol hydrochloride for sustained drug delivery Asian Journal of Pharmacy and Medical Science. Vol 1 (1), 2011 pp1-8.
- 5.Vikas Parashar1,2\*, Dabeer Ahmad1, Surya Prakash Gupta3, Neeraj Upmanyu4, Neha Parashar5, Vinod Mudgal5 Research article Formulation and evaluation of biodegradable microspheres of Tinidazole. International Journal of Drug Delivery 2 (2010) pp238-241
- 6.Ch.Ravi kumar\*,C.Amudha devi, Marichamy.M Vivekraj.J, Department of Pharmaceutics, Ultra College of pharmacy, Madurai, Tamil Nadu Formulation And Evaluation of Chlorzoxazone Microspheres by Thermal Change Method International Journal of Research and Reviews in Pharmacy and applied Sciences (2011) pp 27-32.
- 7.Kataria Sahil1, Middha Akanksha1, Sandhu Premjeet1, Ajay Bilandi and Bhawana Kapoor Microsphere: A Review International Journal of Research in Pharmacy and Chemistry (2011) pp 2231-2781.
- 8.Sanjay Shah, Sarika Madan and SS Agrawal\* Formulation and evaluation of microsphere based oro dispersible tablets of itopride hcl .*DARU Journal of Pharmaceutical Sciences* 2012, 20-24.
- 9.Anand Gadad\*, Chirag Naval, Krunal Patel, Panchaxari Dandagi And Vinayak Mastiholimath Research Article Formulation And Evaluation of Floating Microspheres of Captopril for Prolonged Gastric Residence Time. Indian Journal of Novel Drug Delivery (2011) pp 17-23.
- 10.Suddhasattya Dey, Dhiraj Kumar, D Sandeep Kumar, S.A.Sreenivas 1 and V. Rahul formulation, characterization and in-vitro evaluation of floating microspheres of nateglinide International Journal of Pharma and Bio Sciences (2011) vol 2 pp 147-156.
- 11.Pandya Ketul\*, Prajapati Ghanshyam, Dr. M. R. Patel, Dr. K. R. Patel, Dr. N. M. Patel A Review on Microspheres Internationale Pharmaceutical Sciences vol. 2 2012.
- 12.Vikrant K Nikam1\*,VR. Gudsoorkar2, SN. Hiremath1,R.T. Dolas1 and VA. Kashid1 Review Article MICROSPHERES - A Novel Drug Delivery System International Journal of Pharmaceutical and Chemical Sciences Vol. 1 (1) Jan – Mar 2012
- 13.Hitesh Kumar\*, Koshy M.Kymonil, Shubhini. A. Saraf “Gastro retentive Ethyl Cellulose Floating Microspheres containing Ranitidine Hydrochloride”, Int. J. Drug Dev. & Res., April-June 2012, 4(2): 315-321.
- 14.Nagesh R Sandu1, SP Senthil2\*, and KL Senthilkumar1 Preparation, Characterisation and In-Vitro Study of Microspheres Containing Imatinib Mesylate by Solvent Evaporation Technique Using Ethyl Cellulose. Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences 2013, pp231-342.
- 15.Prasant K Rout, Bhabani S Nayak Research Article Statistical Evaluation Of Losartan Microspheres Prepared By W/O Emulsion Method Using Factorial Design And Response Surface Methodology Asian Journal of Pharmaceutical and Clinical Research Vol.2 Issue 4, October- December 2009

- 16.Meral YÜCE1, Kandemir CANEFE2'Eczacıba i-Zentiva Health Products Co., Lüleburgaz, Turkey Original Article Indomethacin-loaded microspheres of ethylcellulose were prepared by the emulsion solvent evaporation technique Turk J. Pharm. Sci. 5 (3) 129-142, 2008
- 17.Harsh Bansal1, Simar Preet kaur2, Atul Kumar Gupta2 microsphere: methods of prepration and applications; a comparative study International Journal of Pharmaceutical Sciences Review and Research 2011 Page 69.
- 18.J Patel; D Patel; J Ravel formulation and Evaluation of Propranolol Hydrochloride-Loaded Carbopol-934P/Ethyl Cellulose Mucoadhesive Microspheres 2010, Page 221-232
- 19.Kavita Dua, Piyush Trivedi Research article Formulation and evaluation of mucoadhesive microspheres of ranitidine hydrochloride using chitosan and sodium carboxy methyl cellulose as polymers International Journal of Pharmaceutical and Biomedical Research 2013 pp144-147.
- 20.Jayvadan Patela\*, Darshna Patelb and Jignyasha Ravalb Formulation and Evaluation of Propranolol Hydrochloride-Loaded Carbopol-934P/Ethyl Cellulose Mucoadhesive Microspheres Iranian Journal of Pharmaceutical Research (2010), 9 (3): 221-232
- 21.Ramadevi Bhimavarapu\*, Srinath Nissankararao, S. Nagavani, S. Ramadevi and P. Lakshmi Durga Research Article Design, development and in vitro evaluation of gastro retentive alginate floating beads for ranitidine hydrochloride Journal of Chemical and Pharmaceutical Research, 2013, 5(4):377-381

---

**Corresponding Author:**

**Vinod kumar**

**Shri Baba Mastnath Institute of Pharmaceutical Sciences & Research, Asthal Bohar, Rohtak-124001**

**E-mail- jangravinod51@gmail.com**

**Phn no:- +91-8059097345**